The 5th Antifibrotic Drug Development Summit will provide a unique opportunity to gain cross-discipline actionable insights into how the latest scientific research is being applied to fibrosis pipeline progress. Network with industry pioneers in hot areas of drug development, specifically IPF, NASH, scleroderma, IBD, ILD, CKD, and more to apply disease-specific lessons agnostically, and understand how the industry can achieve the crowning glory of pan-fibrosis antifibrotic drugs.

Unmissable Highlights for 2021:

• Join the active discussion surrounding redefining approvable clinical endpoints with the FDA to enhance opportunities for creative clinical trial design and drive your clinical development
• Engage with early initiatives to establish clinical development programs in IBD-associated fibrosis with Cleveland Clinic to kickstart your intestinal fibrosis pipeline as this grows in interest for biopharma
• Investigate the buzz around reprogramming epithelial cells to promote tissue repair in fibrotic disorders with Genentech to understand new strategies for regenerative medicine and overcome mechanistic bottlenecks
• Gain vital insights from Pfizer on how the industry can revolutionize the translatability of current disease models and collaboratively guide the creation of technologies that can better mimic human physiology
• Embrace more successful clinical trial design with an enhanced focus on patient-reported outcomes with Novartis to identify precision medicine approaches, promote patient engagement, and discuss regulatory barriers to novel endpoints

Hear from 35+ industry heavyweights including Genentech, AstraZeneca, FDA, GSK, Boehringer Ingelheim, Pfizer, Takeda, and more to understand transformative mechanistic strategies for promoting tissue regeneration and repair, discover more robust predictive models to improve translatability; and assess emerging non-invasive biomarkers that identify early signs of efficacy and drive successful clinical trials.

To know more visit: https://ter.li/afddpjel